MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585150 | Name: Iotrolan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Iotrolan is a nonionic, isotonic contrast medium designed for intrathecal use.

Chemical Structure

Iotrolan
Iotrolan
CAS#79770-24-4

Theoretical Analysis

MedKoo Cat#: 585150

Name: Iotrolan

CAS#: 79770-24-4

Chemical Formula: C37H48I6N6O18

Exact Mass: 1625.7293

Molecular Weight: 1626.24

Elemental Analysis: C, 27.33; H, 2.98; I, 46.82; N, 5.17; O, 17.71

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Iotrolan; DL 3-117; DL-3117; DL3-117; ZK 39 482; ZK 39482
IUPAC/Chemical Name
1,3-Benzenedicarboxamide, 5,5'-((1,3-dioxo-1,3-propanediyl)bis(methylimino))bis(N,N'-bis(2,3-dihydroxy-1-(hydroxymethyl)propyl)-2,4,6-triiodo-
InChi Key
XUHXFSYUBXNTHU-UHFFFAOYSA-N
InChi Code
InChI=1S/C37H48I6N6O18/c1-48(32-28(40)22(34(64)44-12(4-50)16(58)8-54)26(38)23(29(32)41)35(65)45-13(5-51)17(59)9-55)20(62)3-21(63)49(2)33-30(42)24(36(66)46-14(6-52)18(60)10-56)27(39)25(31(33)43)37(67)47-15(7-53)19(61)11-57/h12-19,50-61H,3-11H2,1-2H3,(H,44,64)(H,45,65)(H,46,66)(H,47,67)
SMILES Code
O=C(N(C1=C(I)C(C(NC(CO)C(O)CO)=O)=C(I)C(C(NC(CO)C(O)CO)=O)=C1I)C)CC(N(C2=C(I)C(C(NC(CO)C(O)CO)=O)=C(I)C(C(NC(CO)C(O)CO)=O)=C2I)C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,626.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lenhard DC, May E, Morgenroth C, Jost G, Haider W, Pietsch H. Adverse skin reactions to iodinated x-ray contrast agents in healthy rats. Invest Radiol. 2014 Dec;49(12):779-87. doi: 10.1097/RLI.0000000000000084. PubMed PMID: 24988006. 2: Sovak M, Ranganathan R, Speck U. Nonionic dimer: development and initial testing of an intrathecal contrast agent. Radiology. 1982 Jan;142(1):115-8. PubMed PMID: 6895557. 3: Iwasaki K, Sudo H, Yamada K, Ito M, Iwasaki N. Cytotoxic effects of the radiocontrast agent iotrolan and anesthetic agents bupivacaine and lidocaine in three-dimensional cultures of human intervertebral disc nucleus pulposus cells: identification of the apoptotic pathways. PLoS One. 2014 Mar 18;9(3):e92442. doi: 10.1371/journal.pone.0092442. eCollection 2014. PubMed PMID: 24642945; PubMed Central PMCID: PMC3958541. 4: Krause W, Bunte T, Schubert R, Blaszkiewicz P. The lack of immunogenicity of iotrolan. Invest Radiol. 1995 Sep;30(9):548-51. PubMed PMID: 8537213. 5: Goebel C, Hardt P, Doppl W, Temme H, Hackstein N, Klör HU. Frequency of pancreatitis after endoscopic retrograde cholangiopancreatography with iopromid or iotrolan: a randomized trial. Eur Radiol. 2000;10(4):677-80. PubMed PMID: 10795554. 6: Miyazawa T, Nakagawa H. [Experimental evaluation of iotrolan as an arthrographic contrast medium--knee arthrography with iotrolan in rabbits]. Nihon Igaku Hoshasen Gakkai Zasshi. 1990 Nov 25;50(11):1381-6. Japanese. PubMed PMID: 2087397. 7: Miyazawa T, Murayama C, Uchimoto R, Fritz-Zieroth B. [Preclinical evaluation of iotrolan as a contrast medium for angiography and urography]. Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Sep 25;52(9):1287-98. Japanese. PubMed PMID: 1437534. 8: Nauert C, Langer M, Mützel W. Hemorrheologic effects of iotrolan after intra-arterial injection in rabbits: comparison with other types of contrast media. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1989;128:40-5. PubMed PMID: 2568806. 9: Wenzel-Hora BI, Potthoff PC, Jänicke UA. Tolerance of iotrolan 190 and cerebrospinal fluid-diluted iotrolan 300 at the same iodine concentration in lumbar myelography. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1989;128:148-52. PubMed PMID: 2568783. 10: Heinrich M, Schneider G, Grgic A, Humke U, Kramann B, Uder M. Effects of dimeric radiographic contrast medium iotrolan on Swine renal arteries: comparison with monomeric contrast media iohexol and iomeprol. Invest Radiol. 2004 Jul;39(7):406-12. PubMed PMID: 15194911. 11: Wagner A, Jensen C, Saebye A, Rasmussen TB. A prospective comparison of iotrolan and iohexol in lumbar myelography. Acta Radiol. 1994 Mar;35(2):182-5. PubMed PMID: 8172748. 12: Miyamoto Y, Tsujimoto T, Iwai K, Ishida K, Uchimoto R, Miyazawa T, Azuma H. Safety and pharmacokinetics of iotrolan in hysterosalpingography. Retention and irritability compared with Lipiodol. Invest Radiol. 1995 Sep;30(9):538-43. PubMed PMID: 8537211. 13: Dooley M, Jarvis B. Iomeprol: a review of its use as a contrast medium. Drugs. 2000 May;59(5):1169-86. Review. PubMed PMID: 10852647. 14: Peachell PT, Morcos SK. Effect of radiographic contrast media on histamine release from human mast cells and basophils. Br J Radiol. 1998 Jan;71(841):24-30. PubMed PMID: 9534695. 15: Mizuno J, Gauss T, Suzuki M, Hayashida M, Arita H, Hanaoka K. Encephalopathy and rhabdomyolysis induced by iotrolan during epiduroscopy. Can J Anaesth. 2007 Jan;54(1):49-53. PubMed PMID: 17197468. 16: Mezilis N, Salame MY, Dyet JF, Arafa SO, Oakley GD, Cumberland DC. Comparison of Iotrolan 320 and Iohexol 350 in cardiac angiography: a randomised double-blind clinical study. Eur J Radiol. 1998 Sep;28(2):171-5. PubMed PMID: 9788025. 17: Press WR, Mützel W, Schöbel C. Tolerance to iotrolan after subarachnoid injection in animals. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1989;128:126-33. PubMed PMID: 2568780. 18: Oldroyd SD, Fang L, Haylor JL, Yates MS, El Nahas AM, Morcos SK. Effects of adenosine receptor antagonists on the responses to contrast media in the isolated rat kidney. Clin Sci (Lond). 2000 Mar;98(3):303-11. PubMed PMID: 10677389. 19: Morcos SK, Anderson PB, Baudouin SV, Clout C, Fairlie N, Baudouin C, Warnock N. Suitability of and tolerance to Iotrolan 300 in bronchography via the fibreoptic bronchoscope. Thorax. 1990 Aug;45(8):628-9. PubMed PMID: 2402728; PubMed Central PMCID: PMC462647. 20: van Bree H, Van Rijssen B, Van Ham L. Comparison of nonionic contrast agents iohexol and iotrolan for cisternal myelography in dogs. Am J Vet Res. 1991 Jun;52(6):926-33. PubMed PMID: 1883098.